Shares of Opexa Therapeutics (OPXA -5.6%) slides after reporting disappointing FY12 results late...

|About: Opexa Therapeutics, Inc. (OPXA)|By:, SA News Editor

Shares of Opexa Therapeutics (OPXA -5.6%) slides after reporting disappointing FY12 results late Thursday, just prior to the long weekend. The company posted a full year net loss of $8.9M versus a loss of $5.97M for 2011, due partly to increased research and other expenses. Additionally, this morning the drug developer announces some changes to its senior managment team, appointing Karthik Radhakrishnan as CFO, Kenny Frazier as VP of Clinical Development and Regulatory Affairs and Maryann Murray as Clinical Development Manager.